Alfica Sehgal
Chief Scientific Officer Judo Bio
Alfica Sehgal, PhD, is the Chief Scientific Officer at Judo Bio and an Entrepreneur-in-Residence at Atlas Venture. A seasoned leader in RNA therapeutics and translational science, she brings over 15 years of experience from prominent roles at Alnylam Pharmaceuticals and CAMP4 Therapeutics, where she served as Head of Discovery and Translation. Dr. Sehgal has a proven track record of advancing novel therapeutic programs from discovery toward the clinic. She holds a PhD and completed postdoctoral fellowships at Yale University and Johns Hopkins University. Her expertise spans target discovery, translational strategy, and building innovative research organizations.
Seminars
Interactive workshop exploring how developers are designing, selecting and optimizing conjugates, ligands and linkers to improve tissue-specific delivery and maximize therapeutic performance. Through expert discussion and practical case studies, attendees will evaluate the critical design decisions that influence target efficiency, manufacturability, safety and long-term platform potential.
Workshop highlights
- Evaluate the latest ligand discovery strategies, comparing established targets such as ASGPR and transferrin receptor with emerging receptor biology to identify new opportunities for tissue-specific delivery
- Explore how linker design influences conjugate performance, understanding the impact of stability, release mechanisms and pharmacokinetics on efficacy, safety and therapeutic index
- Understand the CMC and manufacturing considerations that shape successful conjugate development, including process scalability, raw material selection, technology transfer and the impact of design decisions on manufacturability and clinical supply
- Leave with a practical framework for building a competitive targeting platform, including the key scientific, translational and commercial questions partners and investors will expect your technology to answer before advancing into collaboration or development
